Last reviewed · How we verify
Nadroparin Calcium and Warfarin
Nadroparin calcium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing antithrombin III activity, while warfarin is a vitamin K antagonist that inhibits synthesis of vitamin K-dependent clotting factors.
Nadroparin calcium is a low-molecular-weight heparin that inhibits blood coagulation by enhancing antithrombin III activity, while warfarin is a vitamin K antagonist that inhibits synthesis of vitamin K-dependent clotting factors; together they provide dual anticoagulation. Used for Thromboprophylaxis in high-risk surgical or medical patients, Treatment of venous thromboembolism, Atrial fibrillation with high thromboembolic risk.
At a glance
| Generic name | Nadroparin Calcium and Warfarin |
|---|---|
| Sponsor | Shanghai Zhongshan Hospital |
| Drug class | Anticoagulant combination (low-molecular-weight heparin + vitamin K antagonist) |
| Target | Antithrombin III (nadroparin); Vitamin K-dependent clotting factors II, VII, IX, X (warfarin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Nadroparin calcium works by potentiating antithrombin III to inactivate factors Xa and IIa, providing rapid anticoagulation. Warfarin inhibits the vitamin K-dependent carboxylation of clotting factors II, VII, IX, and X, resulting in delayed anticoagulation. This combination provides both immediate (nadroparin) and sustained (warfarin) anticoagulation for thromboembolic prevention.
Approved indications
- Thromboembolism prevention and treatment
- Atrial fibrillation with thromboembolic risk
Common side effects
- Bleeding
- Thrombocytopenia
- Hematoma at injection site
- Elevated liver enzymes
Key clinical trials
- Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） (PHASE4)
- Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters (PHASE3)
- Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study (PHASE3)
- Safety of Anticoagulant Therapy After Endoscopic Treatment (PHASE4)
- Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices
- Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis (PHASE4)
- Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients
- Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nadroparin Calcium and Warfarin CI brief — competitive landscape report
- Nadroparin Calcium and Warfarin updates RSS · CI watch RSS
- Shanghai Zhongshan Hospital portfolio CI